Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Carsten Stille"'
Autor:
Andreas Reich, Anja Weiß, Lisa Lindner, Xenofon Baraliakos, Denis Poddubnyy, Silke Zinke, Carsten Stille, Anja Strangfeld, Anne C. Regierer
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/432a9caedae541eca13d243ff46b9f09
Autor:
Andreas Reich, Anja Weiß, Lisa Lindner, Xenofon Baraliakos, Denis Poddubnyy, Silke Zinke, Carsten Stille, Anja Strangfeld, Anne C. Regierer
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-12 (2023)
Abstract Background In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA), concomitant depression might have a negative impact on the course of disease and treatment outcomes. The aims of this analysis are to determine the pre
Externí odkaz:
https://doaj.org/article/796b5a293d6f487399a75141e23ac60a
Autor:
Regina Max, Katrin Achilles-Mehr Bakhsh, Kirsten Karberg, Ulrich von Hinüber, Carsten Stille, B. Ehrenstein, Martin Rudwaleit, Klaus Becker, Jürgen Braun, Hans-Hartwig Euler, B. Bannert, N.T. Baerlecken, Reinhold E. Schmidt, Joachim Sieper, Xenofon Baraliakos, S. Zinke, Torsten Matthias, Lars Köhler, Elke Riechers, Jürgen Rech, Adelheid Melzer, Jan Brandt-Jürgens, Karin Rockwitz, Dirk Meyer-Olson, Peter Wagener, Reinhard Hein, Heike-Franziska Weidemann, P. M. Aries, Martin Fleck, Torsten Witte, Eva Schweikhard
Publikováno v:
Arthritis & Rheumatology. 71:729-735
Objective Autoantibodies against CD74 (anti-CD74) are associated with ankylosing spondylitis (AS). The present multicenter study, the International Spondyloarthritis Autoantibody (InterSpA) trial, was undertaken to compare the sensitivity and specifi
Autor:
Anja Strangfeld, Jörn Kekow, Joachim Listing, Angela Zink, A. Richter, Carsten Stille, L. Baganz, Andreas Krause, Arnold Bussmann
Publikováno v:
Rheumatology International
In Germany, Tocilizumab (TCZ) is used for the treatment of rheumatoid arthritis both in biologic-naïve patients and those with previous failures of biologic disease-modifying antirheumatic drugs (bDMARDs). The long-term effectiveness and retention r